文献速递核素与放射性配体治疗肿瘤 PET/CT

联合治疗增强神经内分泌肿瘤肽受体放射性核素治疗

Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-09-06

本文综述了提高177Lu-奥曲肽肽受体放射性核素治疗(PRRT)对神经内分泌肿瘤(NET)疗效的多种联合策略。这些策略包括改善放射性药物递送(增加肿瘤灌注或生长抑素受体密度)和增强辐射诱导DNA损伤的生物学效应。文章还提出对NET患者进行分层以接受联合PRRT的算法,并指出许多联合药物已用于临床,可快速转化。

要点

  • PRRT是转移性NET的有效治疗,但现有方案仅姑息,提高剂量毒性过大。
  • 联合策略可改善放射性药物递送或增强DNA损伤效应以提高疗效。
  • 提出NET患者分层算法,联合药物多已临床使用,可快速转化。

核心结论

  • 联合治疗可在不增加非靶器官辐射毒性的前提下提高177Lu-奥曲肽PRRT对NET的疗效。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 联合策略包括通过增加肿瘤灌注或提高肿瘤表面SSTR密度改善放射性药物递送。
  • 联合策略还包括增强辐射诱导DNA损伤的生物学效应或产生额外DNA损伤负担。

关键数值与推荐

  • 提出对NET患者进行分层以决定是否接受PRRT联合治疗的算法。

临床怎么用

  • 所提联合策略因PRRT和多种联合药物已用于NET及其他癌症患者,可快速转化为临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence of neuroendocrine tumours (NETs) is increasing, but curative therapeutic options are limited because diagnosis is often delayed until the tumour has metastasized. Peptide receptor radionuclide therapy (PRRT) is among the most effective therapeutic options for metastatic NETs because of targeted delivery of radioactivity to the tumour via the somatostatin receptor (SSTR) and relatively low systemic toxicity. However, current PRRT regimes result in palliation rather than cure, and higher doses of PRRT that might achieve remission would also be too toxic to the patients. Therefore, there is a need to improve PRRT of NETs by combining it with other agents to achieve maximum benefits from the internal radiation therapy, while sparing non-target organs from radiation toxicity. Here we review various current and potential combination strategies to improve 177Lu-octreotate-based PRRT of NET, some of which could also apply to other radionuclide therapies. These strategies include co-administered drugs that improve delivery of the radiopharmaceutical via increased tumour perfusion or through increased SSTR density at tumour surface. Other combinations are aimed at enhancing the biological effects of the radiation-induced DNA damage in tumour cells or generating additional DNA damage burden to effectively increase the cytotoxicity of PRRT. We also propose an algorithm for stratifying NET patients to receive or not combination therapies with PRRT. Considering that PRRT and many of these combination agents are already used for treating patients with NET and other cancers, the proposed strategies to improve the efficacy of PRRT could be rapidly translated into the clinic.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Adant S, Shah GM, Beauregard JM, et al. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019. PMID: 31492995. doi:10.1007/s00259-019-04499-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。